U.S. Markets closed

bluebird bio (BLUE) in Focus: Stock Plunges 14.6%

Zacks Equity Research

bluebird bio, Inc. (BLUE) saw a big move last session, as the company’s shares fell by nearly 15% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This stock, trading at a volatile range of $17.69–$27.21 in the past one-month time frame, showed a sharp decline yesterday at $23.25.

This slump shouldn’t be too much of a surprise to investors, as this biotechnology company has seen 2 negative revisions in the past few weeks and its current year earnings consensus has moved lower over the last 30 days. This suggests there may be more trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent slump will continue, as the earnings picture definitely suggests that this might be the case.

BLUE currently has a Zacks Rank #4 (Sell).

Some better-ranked stocks in the Biomed industry include Myriad Genetics Inc. (MYGN), ANI Pharmaceuticals, Inc. (ANIP) and Illumina Inc. (ILMN). All these stocks carry a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

BLUEBIRD BIO INC (BLUE): Free Stock Analysis Report

ILLUMINA INC (ILMN): Free Stock Analysis Report

MYRIAD GENETICS INC (MYGN): Free Stock Analysis Report

ANI PHARMACEUTICALS INC (ANIP): Free Stock Analysis Report

Zacks Investment Research